Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | ACE | P12821 | 4/20 | 0.60 |
| ▸ | ITGB2 | P05107 | 6/20 | 0.59 |
| ▸ | ICAM1 | P05362 | 6/20 | 0.59 |
| ▸ | ITGAL | P20701 | 6/20 | 0.59 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30919264 | 0.85 | ALOX15 (0.67) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL2474927 | 0.85 | LTA4H (0.58) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL2474935 | 0.85 | LTA4H (0.58) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL1994981 | 0.85 | ALOX15 (0.70) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL1994982 | 0.85 | ALOX15 (0.70) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL7745569 | 0.83 | ALOX15 (0.68) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL6426552 | 0.83 | ALOX15 (0.68) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL11369495 | 0.83 | ALOX15 (0.68) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL6313468 | 0.82 | ALOX15 (0.70) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL13278205 | 0.82 | ALOX15 (0.70) | ALOX15ACEITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2264126-A2 | Drug-delivery vehicles based on reversed liquid crystalline phase materials | Lyotropic Therapeutics, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-1677730-B1 | DRUG-DELIVERY VEHICLES BASED ON REVERSED LIQUID CRYSTALLINE PHASE MATERIALS | LYOTROPIC THERAPEUTICS INC (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-1539099-A4 | REVERSED LIQUID CRYSTALLINE PHASES WITH NON-PARAFFIN HYDROPHOBES | LYOTROPIC THERAPEUTICS LLC (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1677730-A4 | DRUG-DELIVERY VEHICLES BASED ON REVERSED LIQUID CRYSTALLINE PHASE MATERIALS | LYOTROPIC THERAPEUTICS INC (US) | 2008-06-11 | — | — | EP | disclosed |
| EP-1677730-A2 | DRUG-DELIVERY VEHICLES BASED ON REVERSED LIQUID CRYSTALLINE PHASE MATERIALS | Lyotropic Therapeutics, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006041878-A2 | PRIMARY EXAMINER | LYOTROPIC THERAPEUTICS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1539099-A2 | REVERSED LIQUID CRYSTALLINE PHASES WITH NON-PARAFFIN HYDROPHOBES | Lyotropic Therapeutics, LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050119340-A1 | Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents | LYOTROPIC THERAPEUTICS, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005034872-A2 | DRUG-DELIVERY VEHICLES BASED ON REVERSED LIQUID CRYSTALLINE PHASE MATERIALS | LYOTROPIC THERAPEUTICS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20040022820-A1 | Reversed liquid crystalline phases with non-paraffin hydrophobes | LYOTROPIC THERAPEUTICS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003106382-A2 | REVERSED LIQUID CRYSTALLINE PHASES WITH NON-PARAFFIN HYDROPHOBES | LYOTROPIC THERAPEUTICS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |